Introduction:
1 2 Osteoarthritis (OA) is a disease characterized by painful deterioration and destruction of articular 3 cartilage 1 . It is a whole joint disease involving, in the case of knee OA, four tissues: cartilage, synovium, 4 meniscus and subchondral bone 2 . OA is a highly heterogeneous condition that makes it difficult to 5 characterize it in terms of clear disease phenotypes 3 or completely understand the pathophysiological 6 processes in terms of responsible biological functions, disease-associated genes and risk loci 4 . Until now 7 there are no disease modifying drugs except for pain-relief treatments and compounds that were used to 8 target the prototypic players involved in inflammation and extracellular matrix (ECM) physiology have 9 not been able to provide significant improvements until now or are still in clinical trials 5 . 10 Systems oriented approaches in OA have been employed in many studies in the past using various 11 experimental platforms and computational methods 6 . One application was to use whole-genome 12 sequencing data (DNA microarray/RNA-seq) to identify overexpressed genes in diseased tissues and 13 pinpoint molecular mechanisms and cellular functions related to OA Error! Reference source not found.7-9 . The 14 latter studies combined this information with other experimental platforms (mass spectrometry 15 proteomics and DNA methylation) or used network based approaches to find pathways regulated during 16 the development of OA. A limitation of differential gene expression and pathway analysis is that it relies 17 on multiple statistical tests and arbitrary cut-off thresholds that are affecting the results 10 . Another 18 approach to process gene expression data is to construct networks using the co-expression of the genes 19 as the connectivity measure 11 . The most prominent method is weighted gene co-expression network 20 analysis (WGCNA) that allows the construction of co-expression networks and the identification of 21 preserved modules between different datasets 12 . Applied to OA, the study by Mueller et al. 13 used 22 WGCNA to identify preserved gene modules comparing human and rat studies. 23
When it comes to drug discovery, systematic approaches using network-based technologies and 'omics 24 platforms are getting increasing attention with many different methodologies developed and applied in 25 the recent years 14 . The core idea is to unravel the molecular mechanisms of diseases and use this 26 information for a systematic evaluation of pharmacological compounds. As an example, the study by 27 Nacher et al. 15 used information from 17 proteomic studies in healthy and OA chondrocytes to develop 28 an OA-interactome and utilized network approaches to identify drugs. 29
Combining these two ideas, using co-expression networks to identify biological functions in OA and 30 then, based on this information, suggesting possible pharmaceutical compounds affecting these 31 functions seems like an interesting option to explore. 32
Thus, the aim of this paper is twofold. At first WGCNA will be used to identify common disease 33 mechanisms in OA joints characterized by preserved gene modules in the relevant tissues (cartilage, 34 synovium, meniscus and subchondral bone). Secondly, based on this information drug candidates will 35 be inferred using network-based approaches. 36
Materials and Methods:
1 2 Datasets 3
Publically available genome-wide microarray datasets for each tissue involved in knee OA were 4 acquired from the Gene Expression Omnibus (GEO) 34 . These included cartilage, synovium, meniscus 5 and subchondral bone. The tissue sources with the GEO accession numbers, the platform and the sample 6 numbers are shown in Table 1 The cartilage dataset (GSE117999) included 24 samples of 12 patients undergoing arthroscopic partial 11 menisectomy without any evidence of OA and 12 patients undergoing total knee arthroplasty due to 12 end-stage OA. The synovium dataset (GSE55235) 35 included 20 samples from 10 healthy individuals 13 and 10 OA patients. The meniscus dataset (GSE98918) 36 included 12 patients undergoing arthroscopic 14 partial menisectomy (healthy) and 12 patients with OA. The subchondral bone dataset (GSE51588) 37 15 included tissue taken from the knee lateral and medial tibial plateaus (LT and MT) of 5 non-OA and 20 16 OA patients. Preliminary analysis of LT vs. MT from the same group showed significant differences in 17 gene expression, thus mixing of tissue from both sites would have resulted in loss of biological 18 information. The MT plateau group showed to be more influenced by OA, thus OA and control groups 19 used the results taken from the MT plateau. 20 21 Data pre-processing and differential expression analysis 22
The R package limma 38 was chosen for background correction and normalisation of the data as well as 23 for the differential expression analysis. RMA and quantile normalisation were used for all datasets as 24 these methods were able to produce MA plots 39 (log-intensity ratio M vs. mean log-intensity A) that 25 were scattered around the zero line, see Supplementary Fig .S1. Before performing differential 26 expression analysis, the gene expression values of normal and OA samples were hierarchically clustered 27 to remove outliers in the respective datasets, see Supplementary Fig. S2 
Weighted gene co-expression network analysis 4
WGCNA is a methodology to identify clusters of genes calculated from a network described by the 5 connectivity of the pairwise correlation between the genes. Further on, it can be used to identify if a 6 module from one dataset is preserved in another dataset by using topological measures of the 7 network Error! Reference source not found. . Detailed information on the methodology can be found in Zhang et 8 al. 12 , therefore just a brief description of the algorithm is presented herein. All computations were 9 performed using the R package WGCNA 40 . The dissimilarity matrix that was used for module identification with WGCNA is defined in equation 6: 32
The procedure of equations (3)-(6) was performed for four datasets and a consensus transformation for 1 the dissimilarity matrices according to equation (7) was computed: 2 3 ( (1) , (2) , . . . ) = ( (1) , (2) , … ) (7) 4 5
Other operators instead of the min operator (10 th quantile, median, mean etc.) can also be used, 6 depending on how strict the consensus criterion is formulated. 7
Finally clusters of genes were identified by using a hybrid method combining hierarchical clustering 8 and partitioning-around-medoids clustering with the consensus matrix of equation (7) as the distance 9 matrix 41 . 10 11
Module stability 12
Two methods to assess the stability of the module identification through the WGCNA algorithm were 13
implemented. The first considered a random removal of 10% of the samples of each microarray dataset 14 with identical processing and module identification as for the original datasets. The second approach 15 used resampling with replacement for the creation of new artificial datasets. Both approaches were 16 performed 50 times with each time comparing the new set of modules with the original set. Multi-dimensional scaling 43 with subsequent k-means clustering 44 on DISCONSMEij was performed to 25 identify clusters of module eigengenes (MEs), so called meta-modules (MMs), that were analysed 26 further down the pipeline. It has to be noted that every MM was again expressed with a meta-module 27 eigengene. 28 At first, it was of interest to what degree the meta-modules were preserved across the datasets. Thus a 29 preservation transformation for the meta-module adjacency matrices AMMij (using equation (3) with β=1) 30 of all four tissues was performed according to equation (8) , further referred as the preservation network: 31
Two measures, the scaled connectivity C and the density D of the preservation network were computed 35 according to equations (9) and (10) to quantify the preservation between networks A (1) and A (2) with 36 dimension n x n. 37
For more detailed information on preservation statistics and differential eigengene network analysis, the 5 reader is referred to Langfelder et al. 42 . 6 7
Module-trait relationship and identification of driver genes 8
Until now the identified MMs represented genes that were co-expressed and preserved across all tissues 9 not considering the phenotype (healthy vs. OA). As a next step it was necessary to point out MMs that 10 have disease related genes. Further on, the connectivity of the genes inside the MMs was of interest, as 11 hub genes might be influential for the according meta-module. 12
Thus, overall gene expression datExpr was correlated to the disease (trait) by computing the gene 13 significance GS with equation (11): 14
Additionally gene connectivity GC was calculated as the weighted within module connectivity (edge 16 weighted degree). 17 18
Functional enrichment and pathway analysis 19
The outcome of the WGCNA analysis are modules of co-expressed genes preserved across knee joint 20 tissues that simultaneously have genes correlated with the disease state. These modules were connected 21 to biological functions and pathways through gene set enrichment analysis (GSEA) using the g:Profiler 22 web-service 45 . g:Profiler takes as an input a listed of gene names (sorted or unsorted) and provides an 23 enrichment score to show if a set of genes is enriched in a biological function or pathway. Enrichment 24 was performed using the Gene Ontology (GO): biological processes 46,47 as well as KEGG 48 and 25 REACTOME 49 pathways. 26
27

Network based drug discovery 28
In order to suggest compounds for treatment of OA, the network-based approach suggested by Guney 29 et al. 33 was used. This approach represents diseases with signatures (lists of proteins or protein encoding 30 genes) that are located in a background protein-protein interaction (PPI) network, called the interactome. 31
Drugs are represented by their respective protein targets (drug signatures) and network-based distances 32 between the disease and drug signatures are used to suggest drugs with therapeutic potential. 33
The disease signature was chosen from the meta-modules of the WGCNA analysis that had genes 34 significantly correlated with the disease state (high GS) and had a high gene connectivity GC. Therefore, 35
following requirements for the disease signature were met: 1: Genes were co-expressed and co-36 expression was preserved across tissues. 2: Genes were correlated with the disease state. 3: Genes were 1 the hub genes of the disease related meta-modules. 2
As the background network a PPI network as presented by Menche et al. 32 consisting of 13460 proteins 3 and 141296 interactions was selected. At first, it was determined if the disease gene list is present as a 4 module in the background network. Two approaches were chosen that quantify the degree to which 5 disease proteins agglomerate in the interactome neighbourhood 32 . The first measure was the module size 6 S quantified by the largest number of disease proteins directly connected to each other. The second one 7 calculated the shortest distance ds as the distance for each disease protein N to the next closest protein 8 associated with the disease inside the interactome. Then the average value <ds> for all disease proteins 9
N describing the diameter of the disease on the interactome was calculated. Detailed explanations can 10 be found in the Supplementary Material of Menche et al. 32 . 11
Random controls were created for both measures S and <ds> from sets with the same number of proteins 12 as the disease signature by sampling without replacement of the background interactome with 13 preservation of the degree distribution. This procedure was repeated 10.000 times and z-scores and p-14 values for S and <ds> were calculated according to equation (12): 15 In the end a list of top 10 drugs with lowest drug-disease proximity and highest significance was derived. 27
In order to validate the findings the function of each compound and their relationship to joint 28 diseases/OA was characterized by literature research returning a hit: compound has relationship with 29 OA in terms of existing studies or pathways/targets relevant for OA or a miss: no interaction between 30 compound and OA/joint diseases. The number of hits were compared to a bottom 10 list of drugs, this 31 means drugs with highest drug-disease proximity and highest statistical significance. Additionally a 32 random 10 list was developed by creating a disease signature through sampling without replacement 33 from the genes of the microarray datasets (11641 overlapping genes) with the same size and degree 34 distribution as S and subsequent drug-disease proximity computation as shown in equation (12) . These 35 two lists have the following reason: The bottom 10 list shows the influence of drug-disease proximity 36 on the chosen compounds, whereas the random 10 list shows the influence of WGCNA in order to select 37 an appropriate disease signature. At last the Drugbank dataset was screened for drugs with curated 1 association to 'arthritis' or 'osteoarthritis' in order to check how a random drug selection from such a 2 list would perform. 3 4 Results: 
11
Preservation of meta-modules across tissues 12
The MM preservation across the tissues was quantified via differential eigengene network analysis (after 13 computing eigengenes for every meta-module) according to equations (8) triangle (F., G., H., K., L., P.) the preservation statistics between two tissues are shown. The height of 20 the bars represent the scaled connectivity C (equation (9)) for each meta-module. The value D represents 21 the density of the preservation network (equation (10)). In both cases values close to 1 mean ideal 22 preservation. For all tissues a median value of D=0.72 can be observed. Pairwise comparisons show that 23 preservation between meniscus and cartilage is almost perfect, whereas subchondral bone vs. cartilage 24 exhibit the worst preservation of D=0. 63 . In the lower triangle (I., M., N., Q., R., S.) the adjacency 25 heatmaps for the pairwise preservation networks of the tissues (equation (8)) are shown with row and 26 columns corresponding to the respective meta-modules. Saturation of red means high preservation. Once 27 again, it can be seen that meniscus and cartilage have a very good preservation whereas the preservation 28 between subchondral bone and cartilage is rather low. In summary, the identified meta-modules are 29 preserved across tissues, however big differences regarding the preservation quality is observable. Until now six meta-modules were identified without any relation to the phenotype or any biological 9 information. Thus, the genes inside the modules were correlated to the OA phenotype via equation (11) 10 (GS) and their intramodular connectivity (GC) was computed. This procedure was repeated for all 11 tissues and a consensus measure was calculated by taking the median value of GS and GC. The results 12 are presented in Figure 4 with the six MMs and the grey module of not-preserved genes. It can be seen, 13 that two MMs, the turquoise and red meta-module exhibit a correlation of 0.45 and 0.4 (p<0.001 in both 14 cases) between gene significance and intramodular connectivity. In other words, the hub genes inside 15 these modules (driver genes) are correlated with the disease and therefore the turquoise and red MMs 16 should be associated with biological functions playing a role in OA. This hypothesis was tested through 17 GSEA in the following step. GSEA was performed on the turquoise and the red MM to see if the preserved modules are involved in 6 common biological functions. As an input a gene list of the according modules sorted by decreasing 7 absolute median t-values taken from the differential expression analysis of each tissue was provided. 8
The results presented in Table 2 show the top 10 pathways and biological processes sorted by the adjusted 9 p values for the red and the turquoise MM. A full list is included in Supplementary Table 1 It can be observed that the red MM mostly represents biological functions and pathways related to the 4 immune system as well as diseases affecting the immune system and causing immune responses. The 5 turquoise MM includes functions related to ECM organization, skeleton and bone development as well 6 as collagen physiology. Involvement of immune system and ECM in OA are well-known facts 2,16 . It was 7 decided to focus the network based drug discovery on genes taken from the turquoise MM, as it showed 8 the most consistent results regarding GS vs. GC correlation in all tissues ( Supplementary Fig.S10 ). 9
Network based drug discovery 11 12 Genes in the 80% quantile of the gene significance (GS) and gene connectivity (GC) of the turquoise 13 MM were chosen. To justify the choice of the threshold for the definition of the disease signature, the 14 agglomeration measures were computed for different percentile values (0-90%) and the respective z-15 scores for module size S and mean shortest distance <ds> were computed. The plots of threshold vs. the 16 agglomeration measures can be found in Supplementary Fig.S11 showing that the 80% threshold 17 provided the best results. This choice resulted in a disease signature of 64 genes with a z-score for the 18 module size S of 12.05 and with a z-score for the mean shortest distance <ds> of -1.75. 19
The results of the drug-disease proximity based screening are shown in Table 3 with the top 10 20 compounds identified by the algorithm. The mean shortest distances between a drug signature and the 21 disease signature are described by <dc>, the respective z-score was computed by 1000 sampling runs 22 with random drug and disease signatures of same size and same degree distribution as the original 23 signatures. As another requirement only drugs with a <dc> ≤ 1 (lowest 5% after screening the full list 24 of 1833 drugs) were considered. The type and mechanism of action were taken from Drugbank. Further 25 on the relation to OA is shown. It can be seen that 4 out of 10 drugs (Ruxolitinib, Certolizumab, 26
Golimumab, Vedolizumab) are anti-inflammatory compounds that, although being used as a treatment 27 for other diseases than OA, have been studied as a treatment option for joint diseases (mostly rheumatoid 28 arthritis). The second finding is that the thrombolytic agent Tirofiban might be an option for treatment 29 of OA. Although there are no studies testing this agent in OA or arthritic joint diseases there exists a 30 clinical study on the linkage of arthritis to local and systemic activation of coagulation and fibrinolysis 31 pathways in a cohort of n=161 patients. The most statistically significant result Florbetapir is a 32 radiopharmaceutical agent that binds to beta amyloid plaque, a molecule playing a central role in 33
Alzheimer's disease (AD). A linkage between AD and OA is a hypothesis that has been posed and 34 positively tested 17 . Finally, hyaluronidase and Turpentine are two compounds that will lead to cartilage 35 destruction by degrading hyaluronan, the major constituent in the ECM (hyaluronidase) and release of 36 inflammatory mediators (Turpentine). Interestingly both compounds are used in disease animal models 1 with hyaluronidase used in OA 18 and Turpentine used in a model of anemia of inflammation 19 . In 2 summary 9 out of 10 suggested compounds exhibit a hit either as having been tested for an arthritic 3 disease or having targets that are also relevant in OA. 
8
In order to validate the compound suggestions the bottom 10 and the random 10 list of drugs were 9 computed. The bottom 10 list is shown in Table 4 . It can be observed that the bottom 10 list does neither 10 include any drugs tested in OA nor any targets relevant for OA. Two random 10 lists were created. The 11 first one was sorted by lowest mean shortest distance <dc> and provided 3 out of 10 hits, however none 12 of them were statistically significant (lowest z-score was -1.3). The second one was sorted by the lowest 13 z-scores and provided 2 out of 10 hits. The lists can be found in Supplementary Table 3 . Even relaxing 14 the requirement of low z-scores and comparing the hits (top 10 vs. random 10) with Fisher's exact test 15 delivers a p-value of 0.02. The results can be found in Supplementary Table 3 . Finally, the entire list of 16 approved drugs (1833 compounds) was screened for having compounds with Drugbank curated 17 application 'arthritis'. In this scenario 42 out of 1833 compounds were selected. Fisher's exact test 18 versus 9 out of 10 hits (top 10 list) delivered a p-value of 4.5e-14. 19 
3
In summary the network based drug discovery approach confirms the role of inflammation in OA and 4 suggests anti-inflammatory agents with various mechanisms of action. Further on, coagulation and 5 fibrinolytic pathways seem to play a role in OA, thus thrombolytic agents might be a treatment 6 opportunity to explore. 7
Discussion:
OA is a multi-tissue disease, including cartilage degradation, meniscus and subchondral bone alterations 3 and synovium inflammation. The aim of the study was to apply WGCNA to identify preserved structures 4 of co-expressed genes, connect these findings to biological functions and include a network based drug 5 discovery approach based on the findings obtained from the WGCNA. 6
The results show that structural similarities in the microarray datasets in terms of co-expressed genes 7 describe biological functions relevant for OA. More specifically two preserved meta-modules had hub 8 genes associated with OA and described functions related to immune system (red MM) and ECM 9 physiology (turquoise MM). It has to be noted that the preservation quality of meta-modules between 10 two tissues was very different (see Figure 3) . Especially meniscus and cartilage show extreme good 11 preservation statistics (D=0.94) which may be caused by several reasons. First of all, in both datasets 12 the healthy samples were retrieved from patients undergoing arthroscopic partial menisectomy whereas 13 the OA samples were retrieved from patients undergoing total knee arthroplasty. Therefore the sample 14 retrieval itself surely poses difficulties in terms of clear separation of the tissues and one cannot exclude 15 the possibility that the cartilage dataset also includes meniscus cells. A second reason might be the use 16 of the exact same platform Agilent-072363 SurePrint G3 Human GE v3 8x60K Microarray 039494 for 17 both datasets. Normally one would not expect such a strong influence on the co-expression of the genes. 18 We tested this hypothesis by performing differential eigengene network analysis after removal of a batch 19 effect of all datasets with the limma package, however the results were not affected. Lastly, there might 20 really be a high overlap of biological functions and a strong similarity between meniscus and cartilage. 21
After meta-module preservation we were interested which modules were relevant for OA for further 22 downstream analysis (see Figure 4 ). In order to allow for a tissue unspecific comparison, the median 23 values of the absolute t-values after differential expression analysis of each tissue were used. 24
Clearly this approach bears the risk of ignoring important biological information that is tissue specific. 25
In particular using the GS vs. GC correlation approach for each tissue individually shows that there are 26 significant differences between the tissues, see Supplementary Results 2. Analysis of the cartilage 27 dataset reveals that there are no meta-modules that exhibit positive correlation between GS and GC. 28 Looking at the differential expression analysis and the volcano plots in Supplementary Table 2 shows 29 that very few genes (n=32) are differentially expressed in this dataset and that most of the genes have 30 low logFC (low spread of the eruption in volcano plot). Further on, differential expression analysis 31 revealed that there are no differentially expressed genes across all tissues, however 8 genes (CSN1S1,  32 APOD, FAP, COL5A2, MXRA5, DEFA3, DEFA4, S100A8) were differentially expressed in 3 out of 33 4 tissues. More details on this analysis can be found in Supplementary Results 4. 34
In the remaining datasets ( Supplementary Fig. S10 A-C) at least either the red or the turquoise MM 35 exhibited a positive correlation between GS and GC. In the synovium dataset the yellow MM seems to 36 be of interest as well. Performing GSEA with g:Profiler on the genes of the yellow MM reveals next to 37 rather generic functions (gene expression, cellular and RNA metabolism) the enrichment of the HIF-1 1 signaling pathway. Comparing with literature reveals many studies proving the role of the hypoxia 2 inducible factor in OA 27, 28 . 3
In addition we ran GSEA for the red, turquoise and yellow MM without any information on the 4 differential expression (just providing an unsorted list of genes). This approach provided basically the 5 same results (in terms of the overall functions of the MM), however the statistical significance was lower 6 in the unsorted case. Finally it has to be added, that there are more sophisticated methods of performing 7 GSEA. Notably, using the piano 29 package allows the consideration of directionality during pathway 8 enrichment, thus identifying which pathways are distinctively up -or down-regulated and how this 9 information relates to the t-values of the differential expression analysis. We created a code that includes 10 the possibility of GSEA with the piano package that is stored in the repository as mentioned in the 11 Materials and Methods section. 12
13
The network based drug discovery approach suggested four compounds with anti-inflammatory 14 potential acting along the JAK/STAT pathway, the TNF-a pathway and the integrin pathway. This is an 15 interesting observation as the genes of the disease signature enriched pathways related to ECM 16 physiology and not to inflammatory processes. Strikingly Vedolizumab, which is a drug for 17 inflammatory bowel disease, ameliorated joint pain and delayed the onset of new cases of joint diseases 18 in a post-hoc analysis of the GEMINI 2 trial 24 . Further on, it was suggested that anti-coagulants might 19 have an effect on osteoarthritis, which is supported by the fact the coagulation and fibrinolysis pathways 20 do play a role in arthritis 21 . The suggestion of two compounds (Hyaluronidase and Turpentine) that 21 would worsen OA conditions shows up the first intrinsic limitation of the drug-disease proximity 22 approach. With this consideration there is no information on positive or negative interactions between 23 target and signature but solely a distance measure between these two groups. Alternative drug screening 24 approaches such as using a reversal of the disease signature (in terms of measured gene expression) such 25 as proposed by the L1000CDS 2 platform might be an interesting alternative 30 . A drawback of such an 26 approach (for our scenario) is that gene expression is very different across the joint tissues and it will be 27 difficult to consider all tissues in parallel. Our validation approach classified the drug suggestions as hits 28 or misses based on literature research and compared them with a bottom 10 list (highest distance) and 29 two random 10 lists (10 compounds with lowest <dc> and 10 compounds with lowest z-score after 30 randomly drawing from gene list of 11461 genes ). In the first case no compounds related to OA were 31 identified. In the second scenario the random 10 lists gave 3 out of 10 hits (without statistically 32 significant z-scores) and 2 out of 10 hits. At last the Drugbank database was screened for compounds 33 including 'arthritis' or 'osteoarthritis' as a curated description, as just random selection from the 34 database without any of the presented analysis steps might be an option. In this case 42 out of 1833 were 35 selected delivering a p-value of 4.5e-14 (Fisher's exact test, compared to 9 out of 10 hits). As the curated 36 description might not be complete, we computed the number of potential arthritis drugs the Drugbank 37 database has to include in order to not be outperformed by the top 10 list. As a result at least 893 out of 1 1833 compounds should have a relation to osteoarthritis in order to deliver a p-value>0.01. As such 2 scenario is highly unlikely, the following conclusions were made: The Drugbank database is not biased 3 towards osteoarthritis drugs. Drug-disease proximity seems like an important measure to be included in 4 drug screening. The analysis performed with WGCNA seems to be necessary in order to prioritize genes 5 of interest and define a disease signature. In the case of OA such signature is not trivially to define. The 6 publications of Menche et al. 32 and Guney et al. 33 based their work on disease signatures obtained from 7 various databases (299 diseases), unfortunately OA is not included in their dataset to allow for a cross-8 check of our results. We tried to overcome the obstacle by choosing a cut-off threshold that produced 9 the lowest z-scores for S and <ds>, thus assuming that the disease signature should be as much 10 agglomerated as possible. Until now the screening was applied to a list of approved drugs in order to 11 facilitate comparison with literature. It can however be easily expanded to include investigational 12 compounds as the only the target genes need to be known. 13
14
Limitations 15
The first limitation in using WGCNA is the requirement of having the exact same list of expressed genes 16 for each tissue, thus it is favourable if the same experimental platform can be used. In our case, the 17 synovium dataset was collected with the Affymetrix platform, whereas the remaining tissues were 18 processed with the Agilent platform. Therefore, in the end, around 11000 genes were used as an input 19 for WGCNA and some information could have gotten lost due to the differences in the experimental 20 platforms. Secondly, although WGCNA tries to reduce the influence of arbitrary cut-off thresholds, the 21 parameter β (equation 3) has to be chosen based on the a priori requirement of scale-free network 22 topology. This assumption might not be correct, as a recent study showed that only a small fraction of 23 biological networks do really exhibit scale-free network properties 31 . As mentioned above, the GSEA 24 performed in the study ignored tissue specificity and directionality measures of the enriched pathways 25 and biological functions. 26
In terms of validation our approach relied on comparison with literature without in vitro testing. It has 27 to be mentioned that in vitro models of OA are rather diverse in terms of model structure, disease 28 induction and model outcome. It is therefore not easy to define whether a drug is really working in 29 comparison to e.g. IC50 in cancer drug testing. Further on, the drug discovery approach was based on 30 molecular profiles of four joint tissues and to the best our knowledge there are no in vitro models 31 considering the influence of all these tissues. Lastly, right now the drug discovery approach does not 32 consider toxicity or side effects in order to include other measures for compound prioritization. 33
34
Despite these limitations we believe that the methodology presented in this work is a viable way to guide 35 in silico drug discovery in OA or other multi-tissue diseases. Having a modular structure, the 36 identification of target genes or the network based drug discovery part can be extended and improved 1 to tackle the abovementioned limitations. 2 3 Overall, WGCNA was used to identify target genes with preserved co-expression across tissues, 4 association with the disease and high intramodular connectivity. The output was used to suggest drugs 5 based on drug-disease proximity measures in a PPI network. Anti-inflammatory compounds with 6 different mechanisms of action such as JAK/STAT inhibitors, TNF-a inhibitors and integrin pathway 7 inhibitors were suggested. Finally compounds affecting the coagulation pathways might be interesting 8 for OA treatment. 
